ExpreS2ion Biotech Holding AB (publ)
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more
ExpreS2ion Biotech Holding AB (publ) (5JD0) - Total Assets
Latest total assets as of September 2025: €61.77 Million EUR
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (publ) (5JD0) holds total assets worth €61.77 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ExpreS2ion Biotech Holding AB (publ) - Total Assets Trend (2021–2024)
This chart illustrates how ExpreS2ion Biotech Holding AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ExpreS2ion Biotech Holding AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
ExpreS2ion Biotech Holding AB (publ)'s total assets of €61.77 Million consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 77.7% |
| Accounts Receivable | €1.19 Million | 1.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.08 Million | 2.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how ExpreS2ion Biotech Holding AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ExpreS2ion Biotech Holding AB (publ)'s current assets represent 90.9% of total assets in 2024, a decrease from 96.4% in 2021.
- Cash Position: Cash and equivalents constituted 77.7% of total assets in 2024, up from 24.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 2.0% of total assets.
ExpreS2ion Biotech Holding AB (publ) Competitors by Total Assets
Key competitors of ExpreS2ion Biotech Holding AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
ExpreS2ion Biotech Holding AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ExpreS2ion Biotech Holding AB (publ) generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ExpreS2ion Biotech Holding AB (publ) is currently not profitable relative to its asset base.
ExpreS2ion Biotech Holding AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.98 | 2.85 | 2.85 |
| Quick Ratio | 1.98 | 2.85 | 2.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €26.54 Million | € 61.55 Million | € 61.55 Million |
ExpreS2ion Biotech Holding AB (publ) - Advanced Valuation Insights
This section examines the relationship between ExpreS2ion Biotech Holding AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 33.3% |
| Total Assets | €104.91 Million |
| Market Capitalization | $1.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values ExpreS2ion Biotech Holding AB (publ)'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ExpreS2ion Biotech Holding AB (publ)'s assets grew by 33.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ExpreS2ion Biotech Holding AB (publ) (2021–2024)
The table below shows the annual total assets of ExpreS2ion Biotech Holding AB (publ) from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €104.91 Million | +33.32% |
| 2023-12-31 | €78.69 Million | -42.71% |
| 2022-12-31 | €137.36 Million | -9.60% |
| 2021-12-31 | €151.96 Million | -- |